FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:712-713 February 28, 2002 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Chronic myelomonocytic leukemia and myelofibrosis with myeloid metaplasia are hematopoietic stem-cell disorders for which there is no effective drug therapy. Imatinib mesylate (Gleevec, Novartis, Basel, Switzerland), formerly known as STI571, is an orally bioavailable derivative of 2-phenylaminopyrimidine that stabilizes an inactive conformation of BCR-ABL and related kinases.¹ One of these kinases is the platelet-derived growth factor receptor.² Because the pathogenesis of both chronic myelomonocytic leukemia and myelofibrosis with myeloid metaplasia may involve signal transduction mediated by platelet-derived growth factor, we initiated two independent pilot studies of imatinib mesylate in these two disorders. We report 3 cases of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pardanani, A., Tefferi, A. (2004). Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104: 1931-1939 [Abstract] [Full Text]